Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutation, most commonly T790M. Through a genome-wide siRNA screen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: de Bruin, Elza C., Cowell, Catherine, Warne, Patricia H., Jiang, Ming, Saunders, Rebecca E., Melnick, Mary Ann, Gettinger, Scott, Walther, Zenta, Wurtz, Anna, Heynen, Guus J., Heideman, Daniëlle A.M., Gómez-Román, Javier, García-Castaño, Almudena, Gong, Yixuan, Ladanyi, Marc, Varmus, Harold, Bernards, René, Smit, Egbert F., Politi, Katerina, Downward, Julian
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011693/
https://ncbi.nlm.nih.gov/pubmed/24535670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0741
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados